Opening Asia for Russia

Indian company starts supply of needle-free ZyCoV-D vaccine

03.02.2022 34 просмотров

The campaign plans to release 10-12 million doses of ZyCoV-D per month.

One of the largest pharmaceutical companies in India, Zydus Cadila, has begun supplying a needle-free ZyCoV-D coronavirus vaccine.

“The company has begun supplying the COVID-19 ZyCoV-D vaccine to the Government of India. The drug is being manufactured at the newly commissioned Center of Excellence for Vaccine Technology at the Biotechnology Park in Ahmedabad,” Zidus Kadila said in a statement released by the Hindustan Times on Wednesday.

ZyCoV-D is the first in the world vaccine based on plasmid DNA. The three-dose vaccine should be given at 28-day intervals. For injections, the needleless PharmaJet system is used instead of a syringe. It is a special injector that injects drops of medicine under pressure onto the human skin, which then penetrate the body. The injector does not affect the nerve endings and is therefore virtually painless to use.

The campaign plans to produce 10-12 million doses of ZyCoV-D per month.

The needle-free vaccine has been approved by the National Regulatory Medicines for Restricted Use in emergencies for children aged 12 and over. Initially, it will be used in the states of Bihar, Jharkhand, Maharashtra and several other states with low coverage of the population with the first dose of the virus vaccine. It will later roll out across the country.

During India's nationwide coronavirus vaccination campaign, about 95% of the country's adult population received the first dose of the COVID-19 vaccine. In January, 60% of Indian children aged 15 to 17 also received the first round of vaccinations.

Новости партнёров